title: 5-FU for genital warts in non-immunocompromised individuals.
abstract: BACKGROUND
  Genital warts are common and usually are harmless but can be painful and psychologically burdensome. Several local treatments can be used, including topical 5-Fluorouracil (5-FU).
  
  
  OBJECTIVE
  To determine the effectiveness and safety of 5-FU topical treatment for genital warts in nonimmunocompromised individuals.
  
  
  METHODS
  Databases searched were Cochrane Central Register of Controlled Trials (The Cochrane Library 2009 Issue 3), MEDLINE (1966 to August 2009), EMBASE (until August 2009), LILACS (1982 to August 2009). The search had no language or publication restrictions.
  
  
  METHODS
  The review included randomised controlled trials (RCTs) among women, men, or both sexes, aged 18 years and older, comparing: 5-FU versus placebo or no treatment; 5-FU in any dose versus other isolated treatment, topical or systemic; 5-FU in any dose associated with other treatment versus placebo; 5-FU in any dose associated with other treatment versus other isolated treatment, topical or systemic; 5-FU in any dose associated with other treatment versus other associated treatment, topical or systemic.
  
  
  METHODS
  Two authors independently assessed trial quality and extracted data from the original publications.
  
  
  RESULTS
  Six trials involving 988 patients (645 women and 343 men) and reporting eight comparisons were found. Two studies reported withdrawals and dropouts, but none mentioned analysis by intention to treat (ITT). 5-FU presented better results for cure than placebo or no treatment (relative risk (RR) 0.39, 95% confidence interval (CI) 0.23 to 0.67), meta-cresol-sulfonic acid (MCSA) (RR 2.11, 95% CI 0.83 to 5.37), Podophylin 2%, 4% or 25% (RR 1.26, 95% CI 0.86 to 1.82). There were no statistical differences for treatment failure for 5-FU versus CO2 Laser (RR 0.69, 95% CI 0.43 to 1.11) versus 5-FU + INFalpha-2a (low dose) (RR 1.02, 95% CI 0.87 to 1.119). Worse results were found for 5-FU versus 5-FU + INFalpha-2a (high dose) (RR 10.78, 95% CI 1.50 to 77.36), and 5-FU + CO2 Laser INFalpha-2a (high dose) (RR 7.97, 95% CI 2.87 to 22.13).
  
  
  CONCLUSIONS
  The reviewed trials were highly variable in methods and quality, and the evidence provided by these studies was weak. Cure rates with several treatments were variable, and although 5-FU presents therapeutic results that are inferior to those seen with 5-FU + Inf alpha-2a (high dose) and 5-FU + CO2 Laser + Inf alpha-2a (high dose), the treatment should not be abandoned. Topical treatment with 5-FU has a therapeutic effect; however, the benefits and risks have not been determined clearly and further studies are needed.
authors.affiliation: Departament of Medicine, Urgency Medicine, Universidade Federal de São Paulo / Escola Paulista de Medicina, Rua Pedro de Toledo 598, São Paulo, SP, Brazil.
authors.forename: Claudio S
authors.initials: CS
authors.lastname: Batista
authors.forename: Alvaro N
authors.initials: AN
authors.lastname: Atallah
authors.forename: Humberto
authors.initials: H
authors.lastname: Saconato
authors.forename: Edina Mk
authors.initials: EM
authors.lastname: da Silva
mesh_terms: D000287:Administration, Topical; D003131:Combined Modality Therapy / Q000379:methods; D003218:Condylomata Acuminata / Q000188:drug therapy*; D003408:Cresols / Q000008:administration & dosage; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage*; D006801:Humans; D007121:Immunocompetence; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage; D054020:Lasers, Gas / Q000627:therapeutic use; D008297:Male; D011034:Podophyllotoxin / Q000008:administration & dosage / Q000031:analogs & derivatives; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins; D013451:Sulfonic Acids / Q000008:administration & dosage
chemical_list: D003408:Cresols; D007166:Immunosuppressive Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D013451:Sulfonic Acids; C507546:podophyllic acid; C042041:3-cresol; D011034:Podophyllotoxin; D005472:Fluorouracil
references.citation: Br J Dermatol. 1975 Jan;92(1):93-6
references.pmid: 1098689
references.citation: Lancet. 2001 Jun 9;357(9271):1831-6
references.pmid: 11410191
references.citation: J Infect Dis. 1986 May;153(5):855-61
references.pmid: 3009636
references.citation: Obstet Gynecol. 1984 Dec;64(6):773-8
references.pmid: 6504421
references.citation: BMC Infect Dis. 2001;1:3
references.pmid: 11401728
references.citation: BMJ. 1994 Nov 12;309(6964):1286-91
references.pmid: 7718048
references.citation: Dermatol Monatsschr. 1975 Dec;161(12):1019-21
references.pmid: 1218683
references.citation: An Esp Pediatr. 2001 Dec;55(6):558-60
references.pmid: 11730592
references.citation: Br Med Bull. 1985 Oct;41(4):361-6
references.pmid: 3902142
references.citation: Int J Gynaecol Obstet. 1995 May;49(2):171-4
references.pmid: 7649323
references.citation: Br J Vener Dis. 1971 Feb;47(1):1-13
references.pmid: 5550858
references.citation: Stat Med. 2002 Jun 15;21(11):1539-58
references.pmid: 12111919
references.citation: J Urol. 1994 Dec;152(6 Pt 1):2011-3
references.pmid: 7966664
references.citation: J Reprod Med. 1991 May;36(5):363-6
references.pmid: 2061884
references.citation: Int J Dermatol. 1995 May;34(5):297-302
references.pmid: 7541783
references.citation: Br J Urol. 1982 Jun;54(3):295
references.pmid: 7049305
references.citation: J Reprod Med. 1994 Oct;39(10):777-80
references.pmid: 7837123
references.citation: Minerva Ginecol. 1996 Jul-Aug;48(7-8):299-302
references.pmid: 8966003
references.citation: Obstet Gynecol Clin North Am. 1996 Sep;23(3):699-706
references.pmid: 8869953
references.citation: Obstet Gynecol. 1986 Dec;68(6):795-9
references.pmid: 3785792
references.citation: J Pediatr. 1989 Jul;115(1):1-9
references.pmid: 2472475
references.citation: Obstet Gynecol Clin North Am. 1987 Jun;14(2):581-8
references.pmid: 2829085
references.citation: Obstet Gynecol. 1986 Dec;68(6):837-41
references.pmid: 3785797
references.citation: Presse Med. 2001 Jun 9;30(20):1017-23
references.pmid: 11433694
references.citation: Adolesc Med. 1996 Feb;7(1):119-130
references.pmid: 10359961
references.citation: Am Fam Physician. 1991 Jan;43(1):143-8
references.pmid: 1846055
references.citation: Obstet Gynecol. 1990 Sep;76(3 Pt 1):439-48
references.pmid: 2166264
references.citation: Cutis. 1998 Dec;62(6):283-5
references.pmid: 9878984
references.citation: Br J Vener Dis. 1977 Aug;53(4):240-3
references.pmid: 922458
references.citation: Obstet Gynecol. 1989 Mar;73(3 Pt 1):312-6
references.pmid: 2915856
references.citation: J Urol. 1975 Feb;113(2):195-8
references.pmid: 1113415
references.citation: Eur J Gynaecol Oncol. 1996;17(6):534
references.pmid: 8971537
references.citation: J Reprod Med. 1990 Apr;35(4):384-7
references.pmid: 2352230
references.citation: J Reprod Med. 1992 May;37(5):453-6
references.pmid: 1324311
references.citation: AMB Rev Assoc Med Bras. 1977 May;23(3):91-2
references.pmid: 368896
references.citation: J Eur Acad Dermatol Venereol. 2002 May;16(3):231-40
references.pmid: 12195562
references.citation: Am J Obstet Gynecol. 1989 Jul;161(1):55-9
references.pmid: 2546429
references.citation: J Urol. 1988 Jul;140(1):53-4
references.pmid: 3379696
references.citation: Hospital (Rio J). 1970 Apr;77(4):1275-80
references.pmid: 4939510
references.citation: Lasers Surg Med. 1988;8(2):135-8
references.pmid: 3367679
references.citation: Acta Derm Venereol. 1976;56(4):297-301
references.pmid: 60026
references.citation: Ann Otol Rhinol Laryngol. 1991 Jun;100(6):479-83
references.pmid: 1647745
references.citation: Eur J Gynaecol Oncol. 1997;18(5):410-3
references.pmid: 9378164
references.citation: JAMA. 1995 Feb 1;273(5):408-12
references.pmid: 7823387
references.citation: N Engl J Med. 1987 Oct 1;317(14):873-8
references.pmid: 2442608
references.citation: Ann Intern Med. 1987 Aug;107(2):224-33
references.pmid: 3300460
references.citation: N Engl J Med. 2003 Feb 6;348(6):518-27
references.pmid: 12571259
references.citation: Commun Dis Rep CDR Suppl. 1999 Dec;9(6):S1-12
references.pmid: 10635605
references.citation: Z Hautkr. 1982 Jun 1;57(11):810-6
references.pmid: 7048776
references.citation: Z Hautkr. 1981 Jan 1;56(1):41-3
references.pmid: 7013310
references.citation: Arch Surg. 1978 May;113(5):630-1
references.pmid: 646625
references.citation: Laryngoscope. 2002 Apr;112(4):700-7
references.pmid: 12150527
references.citation: Carcinogenesis. 2000 Mar;21(3):405-26
references.pmid: 10688861
references.citation: Obstet Gynecol Clin North Am. 1987 Jun;14(2):589-99
references.pmid: 2829086
references.citation: Drugs. 1985 Oct;30(4):368-75
references.pmid: 2415317
references.citation: Obstet Gynecol. 1987 Jul;70(1):68-71
references.pmid: 3601270
references.citation: Z Hautkr. 1986 Apr 1;61(7):463-9
references.pmid: 3705667
references.citation: J Infect Dis. 2002 Sep 15;186(6):737-42
references.pmid: 12198606
references.citation: Arch Otolaryngol Head Neck Surg. 1987 Aug;113(8):882-4
references.pmid: 3620153
references.citation: Int J STD AIDS. 2000 Jun;11(6):371-4
references.pmid: 10872909
references.citation: Eur J Gynaecol Oncol. 1996;17(6):529-33
references.pmid: 8971536
references.citation: Epidemiol Rev. 1988;10:122-63
references.pmid: 2852116
references.citation: J Virol. 2002 Feb;76(3):1533-6
references.pmid: 11773428
references.citation: Ann N Y Acad Sci. 1988;549:1-265
references.pmid: 3228249
references.citation: South Med J. 1990 Jul;83(7):761-4
references.pmid: 2371597